← Back to Clinical Trials
Recruiting NCT06314113
Evaluation of Oral EGCG Treatment for L-SIL Associated With HPV Infection
Trial Parameters
Condition Low-Grade Intraepithelial Neoplasia of Cervix
Sponsor University of Palermo
Study Type OBSERVATIONAL
Phase N/A
Enrollment 50
Sex FEMALE
Min Age 18 Years
Max Age 65 Years
Start Date 2024-03-01
Completion 2025-03-01
Interventions
Epigallocatechin Gallate
Brief Summary
The study aims to evaluate the effectiveness of the synergy of oral Epigallocatechin Gallate as a treatment for Low-grade Cervical Lesions (L-SIL) associated with Human Papilloma Virus (HPV) infection.
Eligibility Criteria
Inclusion Criteria: * Women affected by Low-grade Cervical Lesions (L-SIL) associated with Human Papilloma Virus (HPV) Infection Exclusion Criteria: * Pregnancy * Concomitant pathologies causing immunosuppression * Concurrent Immunomodulatory therapies * Hormone replacement therapy * High-grade Cervical Lesions (H-SIL) or in situ adenocarcinoma * Previous history of L-SIL or higher grade lesions ≥ 24 months